Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
暂无分享,去创建一个
Michael Gnant | Jonas Bergh | Richard Greil | Mats Hellström | Daniel Egle | R. Greil | J. Bergh | P. Malmström | M. Gnant | S. Loibl | M. Untch | C. Singer | G. von Minckwitz | G. Steger | N. Bengtsson | H. Johansson | Y. Brandberg | T. Fornander | T. Foukakis | H. Anderson | B. Mlineritsch | D. Egle | Gunter von Minckwitz | Hemming Johansson | Harald Anderson | Sibylle Loibl | Michael Untch | Theodoros Foukakis | Nils-Olof Bengtsson | Yvonne Brandberg | Birgitta Wallberg | Tommy Fornander | Brigitte Mlineritsch | Sabine Schmatloch | Christian F Singer | Günther Steger | Eva Karlsson | Lena Carlsson | Per Malmström | Volker Möbus | V. Möbus | L. Carlsson | S. Schmatloch | B. Wallberg | E. Karlsson | M. Hellström
[1] L. Freedman. Tables of the number of patients required in clinical trials using the logrank test. , 1982, Statistics in medicine.
[2] H J Tagnon,et al. The European Organization for Research on Treatment of Cancer. , 1986, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[3] L. Norton. A Gompertzian model of human breast cancer growth. , 1988, Cancer research.
[4] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[5] Andrew Bottomley,et al. EORTC QLQ-C30 Scoring Manual , 1995 .
[6] N. Aaronson,et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.
[8] A. Auvinen,et al. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. , 1997, British Journal of Cancer.
[9] A. Goldhirsch,et al. Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer , 1998 .
[10] L. Grochow,et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. , 2002, Journal of the National Cancer Institute.
[11] G. Kerr,et al. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer , 2003, British Journal of Cancer.
[12] Barbara L. Smith,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.
[14] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .
[15] J. Bergh,et al. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] E. Perez,et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.
[17] L. Leibovici,et al. Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials , 2010, Journal of the National Cancer Institute.
[18] Andreas Schneeweiss,et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Bergh,et al. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer , 2011, Acta oncologica.
[20] Tanja Cufer,et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. , 2011, The Lancet. Oncology.
[21] E. Perez,et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] D. Cutter,et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.
[23] S. Barni,et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial , 2015, The Lancet.